Cover Image

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer

Mitsukuni Suenaga,1 Nobuyuki Mizunuma,1 Satoshi Matsusaka,1 Eiji Shinozaki,1 Masato Ozaka,1 Mariko Ogura,1 Keisho Chin,1 Toshiharu Yamaguchi2 1Department of Gastroenterology, 2Department of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Res...

Full description

Saved in:

Bibliographic Details
Main Authors:	Suenaga M (Author), Mizunuma N (Author), Matsusaka S (Author), Shinozaki E (Author), Ozaka M (Author), Ogura M (Author), Chin K (Author), Yamaguchi T (Author)
Format:	Book
Published:	Dove Medical Press, 2015-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study
by: Suenaga M, et al.
Published: (2015)

CAPECITABINE AND IRINOTECAN AS FIRST- LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER
by: Deyan Davidov
Published: (2010)

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024)

BEVACIZUMAB COMBINED WITH IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN AS THE FIRST- LINE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA
by: Deyan Davidov
Published: (2014)

Real-world comparison between weekly versus biweekly dosing of cetuximab for metastatic colorectal cancer
by: Himani Aggarwal, et al.
Published: (2023)

IRINOTECAN, FLUOROURACIL AND LEUCOVORIN IN PATIENTS WITH METASTATIC COLORECTAL CANCER
by: Deyan Davidov
Published: (2008)

miR-7, miR-10a and miR-143 Expression May Predict Response to Bevacizumab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer
by: Romero-Lorca A, et al.
Published: (2021)

Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer
by: Toshiki Masuishi, et al.
Published: (2023)

FIRST LINE 5-FU-BASED CHEMOTHERAPY WITH/WITHOUT BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER: TISSUE BIOMARKER CANDIDATES
by: Assia Konsoulova, et al.
Published: (2016)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022)

Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatinand irinotecan-based chemotherapy and biologics in the US
by: Victoria Federico Paly, et al.
Published: (2024)

Salvage Chemotherapy in Recurrent Cervical Cancer With Biweekly Pegylated Liposomal Doxorubicin (Lipo-Dox)
by: Jen-Ruei Chen, et al.
Published: (2008)

Impact of bevacizumab on clinical outcomes and its comparison with standard chemotherapy in metastatic colorectal cancer patients: a systematic review and meta-analysis
by: Tehnia Naz, et al.
Published: (2024)

Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters
by: Esther Oyaga-Iriarte, et al.
Published: (2019)

Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer
by: Mohsin Hamid, et al.
Published: (2018)

Traditional Chinese Medicine Combined With Chemotherapy and Cetuximab or Bevacizumab for Metastatic Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
by: Ningning Liu, et al.
Published: (2020)

ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients
by: Pau Riera, et al.
Published: (2020)

The effective combination therapies with irinotecan for colorectal cancer
by: Yun Chai, et al.
Published: (2024)

Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer-the Experience of a Tertiary Cancer Center
by: Călin Căinap, et al.
Published: (2021)

Racial disparities in metastatic colorectal cancer outcomes revealed by tumor microbiome and transcriptome analysis with bevacizumab treatment
by: Lei Feng, et al.
Published: (2024)

Clinical risk factors of bevacizumab-related hypertension in patients with metastatic colorectal cancer: a retrospective study
by: Zhuoling Zheng, et al.
Published: (2024)

Rs11479 in Thymidine Phosphorylase Associated with Prognosis of Patients with Colorectal Cancer Who Received Capecitabine-Based Adjuvant Chemotherapy
by: Jia X, et al.
Published: (2023)

Metastatic colorectal cancer and severe hypocalcemia following irinotecan administration in a patient with X-linked agammaglobulinemia: a case report
by: Mingming Li, et al.
Published: (2019)

Clinical pharmacokinetics of capecitabine and its metabolites in colorectal cancer patients
by: Saeed Alqahtani, et al.
Published: (2022)

Clinical case use bevacizumab for patient with metastatic ovarian cancer
by: M. R. Oganyan, et al.
Published: (2014)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
by: Pingyu Chen, et al.
Published: (2022)

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab
by: Affronti ML, et al.
Published: (2016)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
by: Ting Zhou, et al.
Published: (2022)

Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now?
by: Lakshmi Chintala, et al.
Published: (2011)

Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer
by: Jinwei Zhu, et al.
Published: (2023)

Evaluation of the Expression Profile of Irinotecan-Induced Diarrhea in Patients with Colorectal Cancer
by: Mashiro Okunaka, et al.
Published: (2021)

Comparative efficacy and safety of Chinese medicine injections combined with capecitabine and oxaliplatin chemotherapies in treatment of colorectal cancer: A bayesian network meta-analysis
by: Shuzhen Liu, et al.
Published: (2022)

Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase
by: Bei Yue, et al.
Published: (2021)

Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First‐Line Gastric Cancer and Elevated Plasma VEGF‐A
by: Kelong Han, et al.
Published: (2016)

Capecitabine safety profile, innovative and generic adjuvant formulation of nonmetastatic colorectal cancer
by: Julia Sánchez-Gundín, et al.
Published: (2019)

Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer
by: Thérèse H Franco, et al.
Published: (2008)

Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer
by: Jing Wang, et al.
Published: (2023)

Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies
by: Xiuwen Guan, et al.
Published: (2023)

Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L
by: Adrien Labriet, et al.
Published: (2017)

Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
by: Ruijia Chen, et al.
Published: (2022)